Skip to main content
. 2016 Jun 24;95(25):e3865. doi: 10.1097/MD.0000000000003865

Figure 1.

Figure 1

Survival differences for luminal B, HER2-positive, and TNBC subtypes compared with luminal A (followed up for at least 3 years). HER2 = human epidermal growth factor 2, n = number of events, N = number of patients at risk, OS = overall survival, PFS = progression-free survival, TNBC = triple negative breast cancer.